Denali Therapeutics Inc. DNLI Business Segments — Research and Development Expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Denali Therapeutics Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Denali Therapeutics Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Denali Therapeutics Inc.'s business segments — research and development expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Denali Therapeutics Inc.'s business segments — research and development expense?
- Denali Therapeutics Inc. (DNLI) reported business segments — research and development expense of $103.85M in Q1 2026.
- How has Denali Therapeutics Inc.'s business segments — research and development expense changed year-over-year?
- Denali Therapeutics Inc.'s business segments — research and development expense decreased by 10.7% year-over-year, from $116.23M to $103.85M.
- What is the long-term trend for Denali Therapeutics Inc.'s business segments — research and development expense?
- Over 3 years (2022 to 2025), Denali Therapeutics Inc.'s business segments — research and development expense has grown at a 5.3% compound annual growth rate (CAGR), from $358.73M to $418.78M.
- What does business segments — research and development expense mean?
- The total aggregate cost of all research and development activities, including internal personnel, external collaborations, and overhead. This is a primary indicator of the company's commitment to advancing its clinical and preclinical pipeline. Investors use this to evaluate the company's burn rate and the scale of its scientific investment.